Healthcare / BiotechnologyNasdaqCM
$1.81
-0.01 (-0.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-935118.00 · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$4M
P/E
0.0x
↓EV/EBITDA
N/A
•ROE
-423.7%
↓Gross Margin
N/A
•Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-58.9M · FCF $-405168.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Net Income | $-58.9M | $-58.9M | $-1.8M | $-2.7M | $-2.7M | $-2.0M | $-4.7M | $-5.8M | $-7.0M | $-7.9M | $-9.4M | $-3.4M | $-829564.00 | $-1.4M | $-11.4M | $-2.2M | $-842487.00 | $-443849.00 |
| EBITDA | $-58.3M | $-58.3M | $-1.3M | $-2.2M | $-2.1M | — | — | — | — | — | — | — | — | $-1.4M | $-11.6M | $-2.2M | — | — |
| EPS | -14.85 | -14.85 | -1420.53 | -781709.75 | -1119475.67 | -40.00 | — | — | — | — | — | — | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.12 | 0.12 | -0.25 | -0.18 | -0.34 | -0.20 | -0.43 | -0.39 | -0.70 | -0.64 | -0.47 | — | — | — | — | — | — | — |
| Current Ratio | 2.37 | 2.37 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-405168.00 | $-405168.00 | $-935118.00 | $-1.1M | $-1.4M | — | — | $-2.1M | — | — | — | — | $226442.00 | $-2.7M | $-185064.00 | $-1.4M | — | — |
| Returns | ||||||||||||||||||
| ROE | -423.7% | -423.7% | 48.2% | 85.4% | 87.9% | 66.0% | 130.2% | 133.9% | 104.3% | 144.6% | 366.8% | 111.8% | 58.9% | 182.0% | 2125.7% | -20.5% | 450.8% | 108.4% |
| Valuation | ||||||||||||||||||
| P/E | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.52 | 0.52 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| EPS Growth | 99.0% | 99.0% | 99.8% | 30.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-96.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1420.53 → -14.85
Residual
-96.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.